Abstract Background. Accumulating evidence shows that chronic kidney disease (CKD) is an independent risk factor for major adverse cardiac and cerebrovascular events (MACCE) after acute coronary syndrome (ACS). However, it is not known whether mild renal insufficiency affects long-term clinical outcomes.
(eGFR) at time of ACS: moderate-to-severe CKD, <60 mL/ min/1.73 m 2 (n ¼ 31, 17.2%); mild CKD, 60-90 mL/min/ 1.73 m 2 (n ¼ 100, 55.6%) and non-CKD, !90 mL/min/1.73 m 2 (n ¼ 47, 26.1%). The eGFR was calculated using the new Japanese equation. Long-term outcomes were compared over a follow-up period of 1538 6 707 days.
Results. Cumulative incidence rates of MACCE did not significantly differ between groups 1 year after ACS onset (P ¼ 0.384), whereas significant differences appeared during the long-term follow-up (10.6 versus 27.0% versus 35.4% in the non-CKD, mild CKD and moderate-to-severe CKD groups, respectively; log-rank test, P ¼ 0.022). In a multivariate Cox hazard regression model, moderateto-severe CKD and mild CKD were associated with a higher rate of MACCE after adjusting for confounding variables (hazard ratios ¼ 3.46 and 2.67, respectively; P ¼ 0.043).
Conclusions. The presence of mild CKD at ACS occurrence is associated with a worse outcome in the long term, but not the short term.
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Background
Chronic kidney disease (CKD) is strongly associated with a higher risk of cardiovascular disease, and the presence of CKD is a potent predictor of a worse prognosis among patients with coronary artery disease [1] [2] [3] [4] . Percutaneous coronary intervention (PCI) is being performed in an increasingly wider spectrum of patients, including those with CKD, though poor clinical outcomes have been demonstrated in patients with end-stage renal disease [5] [6] . Mild to severe renal dysfunction has been further implicated in a worse short-term outcome after acute coronary syndrome (ACS) regardless of the specific treatment modality [7] [8] . Although several studies have demonstrated the negative effect of moderate-to-severe CKD on short-term clinical outcome after PCI, no prospective cohort studies have examined whether ACS patients with mild CKD are at an increased risk for cardiovascular events after PCI in the long term. In addition, the association between glomerular filtration rate estimated by the new Japanese equation and long-term prognosis has not yet been reported. We explored the impact of mild CKD on long-term clinical outcomes of patients enrolled in the Extended-ESTABLISH trial. All patients had ACS and underwent successful PCI; patients with mild CKD were compared with those with normal renal function and moderate-to-severe CKD.
Materials and methods

Study design and patients
This is a post-hoc analysis from the Extended-ESTABLISH trial, which was designed to estimate the impact of renal insufficiency on patients with ACS after PCI over the long term. The Extended-ESTABLISH study, an extended version of the ESTABLSIH trial, has been described in detail [9] [10] . Briefly, the Extended-ESTABLISH trial was a prospective open-label, randomized, single-center study of patients with ACS for whom PCI had been successful. Patients were eligible for inclusion if they had ACS with significant stenosis on initial coronary angiograms and underwent PCI. ACS was defined as high-risk unstable angina, non-ST-elevated myocardial infarction (MI) or ST-elevated MI. An increase (!2-fold) in serum creatine phosphokinase and troponin T positivity indicated a diagnosis of MI. Exclusion criteria included failed PCI, diseased bypass graft, recommended for coronary artery bypass surgery, cardiogenic shock and already receiving lipid-lowering drugs (statins, clofibrate, probucol or analogs, nicotinic acid or other prohibited drugs) at the time of enrollment.
In the Extended-ESTABLISH trial, 180 ACS patients undergoing PCI under intravascular ultrasound guidance were enrolled between November 2001 and July 2005. Patients were randomized within 48 h of ACS onset to receive either intensive lipid-lowering therapy (atorvastatin 20 mg p.o. daily) immediately after the PCI procedure or standard care (lipid-lowering diet). Six months after ACS onset, structured treatment was discontinued for all patients in both groups. Thereafter, their attending physicians administered statins to achieve a low-density lipoprotein-C value of <100 mg/dL. Our institutional review board approved the study protocol, and written informed consent was obtained from each patient.
Determination of renal function
Baseline data at the time of ACS were used to evaluate renal function. We used the estimated glomerular filtration rate (eGFR) based on the new Japanese coefficient-modified Modification of Diet in Renal disease (MDRD) study equation [11] . The formula is as follows: eGFR ¼ 194 3 serum creatinine (SCr) À1.094 3 age
À0.287
, where age is in years, SCr is in mg/dL and glomerular filtration rate (GFR) is in mL/min/1. 
Clinical end-points
The primary end-point was the first occurrence of major adverse cardiac and cerebrovascular events (MACCE), that is, all-cause death, recurrent ACS and stroke. Recurrent ACS was defined as acute MI and unstable angina requiring emergency hospitalization for either PCI or coronary artery bypass grafting. Stroke was diagnosed based on the presence of a neurologic deficit that was confirmed by computed tomography or magnetic resonance imaging.
Outcome data were collected by serial contact with the patients or their families until 31 August 2008. The medical records of patients who died or who were treated at our hospital were analyzed. Other institutions that admitted patients provided details and causes of death.
Statistical analyses
Continuous variables are expressed as means AE SDs. Data from pairs of groups were compared using the t-test or the Wilcoxon rank-sum test, and intra-group data were analyzed using the paired t-test or the Wilcoxon signed-rank test. Categorical data were tabulated as frequencies and percentages and compared using the v 2 test or Fisher's exact test. Event-free survival probabilities for MACCE were estimated using the Kaplan-Meier method, and group differences were assessed using a log-rank test. Hazards ratios for outcomes were estimated using the Cox proportional hazards model comparing the mild CKD and the moderate-to-severe CKD groups with the non-CKD group. Unadjusted hazard ratios for confounding variables, including age, serum creatinine, gender, hypertension, diabetes, early atorvastatin treatment for 6 months and eGFR, were calculated using the Cox proportional hazards model. We also computed adjusted hazard ratios with the multivariate Cox hazard model including all the above variables. A two-sided P-value of <0.05 was considered significant. All data were analyzed using JMP version 7.0 for Windows (SAS Institute, Cary, NC).
Results
Baseline characteristics
Mean values for age, serum creatinine levels and eGFR at the time of ACS were 62.6 AE 10.4 years, 0.85 AE 1.02 mg/dL and 78.2 AE 22.5 mL/min/1.73 m 2 , respectively. Forty-seven (26.1%) patients were classified as having normal renal function (non-CKD group), 100 (55.6%) were classified as having mild CKD and 31 (17.2%) were classified as having moderate-to-severe CKD. Baseline characteristics were similar among the three groups, except for significant differences in age and serum creatinine levels (Tables 1 and 2 ). We did not observe differences in the prevalence of comorbidities such as hypertension or diabetes across the range of renal function categories. Two patients in the moderate-to-severe CKD group began maintenance hemodialysis during hospitalization. Furthermore, the ratio of patients receiving atorvastatin 20 mg/day for 6 months in the Extended-ESTABLISH trial was the same among the three groups (P ¼ 0.610). All patients received bare metal stents to treat ACS.
Short-and long-term outcomes
Prognostic data were fully documented during the entire follow-up period [mean duration, 1538 AE 707 days (4.2 AE 1.9 years)]. Cumulative incidence rates of MACCE in the short term did not significantly differ among the three groups at 6 months or 1 year (6.4 versus 9.0 versus 19.4%; P ¼ 0.302, 6.4 versus 12.0 versus 19.4%; P ¼ 0.384, respectively). On the other hand, there were significant differences among cumulative event-free survival over the long term among groups, during which MACCE developed in five patients in the non-CKD group (death, n ¼ 1; ACS, n ¼ 4), 27 in the mild CKD group (death, n ¼ 6; ACS, n ¼ 18; stroke ¼ 3) and 11 in the moderate-to-severe CKD group (death, n ¼ 3; ACS, n ¼ 6; stroke ¼ 2) (10.6 versus 27.0 versus 35.4%, respectively, logrank test; P ¼ 0.022; Figure 1 ). Both the moderate-to-severe CKD group and the mild CKD group presented with a significantly higher rate of MACCE than the non-CKD group (P ¼ 0.018 and P ¼ 0.042, respectively). There were no significant differences between the moderate-to-severe CKD and mild CKD groups (P ¼ 0.495). We also divided patients into groups based on quartiles of baseline eGFR: first quartile, mean eGFR, 52. . The cumulative incidence rates of MACCE in the long term significantly differed among the four groups (P ¼ 0.025). Patients in first quartile had better clinical outcomes than patients in the other three groups (Figure 2 ).
Predictors of long-term clinical outcome
We conducted an unadjusted Cox proportional hazards model to detect long-term predictors for MACCE. Modeling of GFR as a continuous variable resulted in a significant association with MACCE [hazard ratio for every 10 mL/min/1.73 m 2 decrease of GFR: 1.30; 95% confidence interval (CI): 1.14-1.49; P < 0.001]. By using the adjusted Cox proportional hazard model, adjusted for age, serum creatinine, gender, hypertension, diabetes, early atorvastatin therapy and eGFR, a significant predictive effect for MACCE was observed for early statin therapy (hazard ratio, 0.51; 95% CI, 0.26-0.94; P ¼ 0.032) and eGFR (hazard ratio for every 10 mL/min/1.73 m 2 decrease of GFR, 1.31; 95% CI, 1.13-1.51; P < 0.001) ( Table 3 ). In addition, the risk of CKD for MACCE in the long term was evaluated using the Cox proportional hazards model. We observed that patients with mild CKD had a 2.99-fold increased risk of MACCE in the unadjusted model and a 2.67-fold increased risk of MACCE in the adjusted model compared with the non-CKD group (P ¼ 0.013 and P ¼ 0.043, respectively). Patients with moderate-to-severe CKD also had a significant risk for MACCE compared with the non-CKD group (4.00-fold in the unadjusted model and 3.46-fold in the adjusted model), as well as compared with the mild CKD group (1.34-fold in the unadjusted model and 1.28-fold in the adjusted model, P ¼ 0.416 and P ¼ 0.495, respectively) (data not shown) ( Table 4) . 
Discussion
The present study demonstrated that MACCE is increased in patients with mild CKD or moderate-to-severe CKD over the long term after successful PCI treatment for ACS. Moreover, even after adjustment for important factors by multivariable Cox regression models, both moderate-to-severe CKD and mild CKD remain as significant predictors of negative long-term clinical outcomes after ACS. We also found that when we used the new Japanese equation, eGFR values were associated with an increased risk for MACCE in patients with ACS.
Results of the present study showed that even the presence of mild CKD at the time of ACS and PCI was associated with a worse prognosis in the long term. CKD is inherently linked to other important cardiovascular risk factors and clinical manifestations associated with a higher incidence of adverse events after PCI or coronary artery bypass grafting [12] [13] . It has been suggested that four main factors contribute to this impaired prognosis: excess comorbidities, underuse of beneficial treatment strategies, toxicity of therapy and abnormal vascular pathology of CKD [14] . In addition, related conditions such as diabetes and hypertension, as well as the presence of renal insufficiency itself, lead to activation of the renin-angiotensin system, oxidative stress, elevated asymmetric dimethylarginine, low-grade inflammation with increased circulating cytokines and dyslipidemia, which are all common pathophysiological mechanisms that play a role in the association of renal insufficiency and cardiovascular events [15] . Furthermore, as observed in patients with CKD, the reduction in the number of and impaired function of endothelial progenitor cells, known to have a beneficial impact in cardiovascular disease after PCI when endothelial healing is critical, might contribute to the poor outcome in our study [16] [17] . Our results demonstrate that relatively minor renal insufficiency, such as a slightly reduced GFR, may be associated with increased risk of MACCE in the long term; this increased risk is most likely based on one or more of the mechanisms described.
The long-term follow-up after ACS showed a negative effect of mild CKD on the post-PCI outcomes extending Fig. 1 . Kaplan Meier curves for the incidence of MACCE according to three renal function groups based on findings using the MDRD study equation (non-CKD, mild CKD and moderate-to-severe CKD) in longterm follow-up. Cumulative event-free survival revealed a significant difference among the three groups (log-rank test, P ¼ 0.023). Fig. 2 . Kaplan-Meier curves for the incidence of MACCE according to four renal function groups based on quartiles of baseline eGFR: first quartile group (mean eGFR, 52.3 6 13.2 mL/min/1.73 m 2 ), second quartile (69.6 6 3.9 mL/min/1.73 m 2 ), third quartile (82.9 6 4.4 mL/min/1.73 m 2 ) and fourth quartile (107.9 6 13.6 mL/min/1.73 m 2 ). Cumulative incidence rates of MACCE in the long term significantly differed among the four groups (log-rank test, P ¼ 0.025).
well beyond a few years, which is the follow-up limit of most other studies [6] [7] 18] . We observed similar clinical outcomes up to 3 years between the non-CKD and mild CKD groups, whereas a significant diversion in MACCE was observed afterward. The cumulative event-free rate in the mild CKD group was almost the same rate~5 years compared with the moderate-to-severe CKD group. Although there was clinical evidence of CKD (eGFR < 60 mL/min/1.73 m 2 ) in patients with coronary artery disease, we believe that the impact of mild CKD (eGFR 60-90 mL/min/1.73 m 2 ) in patients with ACS might still be underestimated in clinical practice. Therefore, we believe our study demonstrates the clinical significance of mild renal insufficiency over the long term after ACS. Thus, more active intervention might be needed for mild CKD from the early stage in the secondary prevention of coronary artery disease.
The present study also showed that early intensive atorvastatin treatment for 6 months was a good predictor for MACCE in patients with ACS after adjustment for confounding factors, including eGFR. In another report, compared with usual care, focused atorvastatin treatment decreased cardiovascular risk for the patients with coronary artery disease in real-world settings, with no significant difference in treatment effects observed between patients with or without CKD [19] . Similarly, in patients with mildto-moderate CKD in major statin trials, data suggest that not only lower doses but also aggressive high-dose statins are effective in preventing cardiovascular events [20] [21] . Recent recommendations of the National Lipid Association Statin Safety Assessment Task Force indicate that CKD should not preclude use of a statin [22] . Accordingly, we believe that early statin treatment should be initiated in all patients with ACS, regardless of their renal function.
We also believe that near normal renal function might not be valid with the original MDRD equation. Indeed, the MDRD Study equation is the most commonly used equation to estimate GFR worldwide, including in Japan. However, Levey et al. [23] recently developed a new, more accurate GFR estimation, the CKD Epidemiology Collaboration (CKD-EPI) equation. In addition, another report from Japan demonstrated that the Japanese coefficientmodified CKD-EPI equation yields a lower estimated , where SCr is serum creatinine, j is 0.7 for females and 0.9 for males, a is À0.329 for females and À0.411 for males, min indicates the minimum of SCr/j or 1 and max indicates the maximum of SCr/j or 1 [24] . prevalence of CKD than the Japanese coefficient-modified MDRD study equation [24] . Thus, we calculated eGFR using the Japanese CKD-EPI equation. As a result, 28 (15.7%) patients were classified in our study as having normal renal function (non-CKD group), 135 (75.8%) were classified as having mild CKD and 15 (8.4%) were classified as having moderate-to-severe CKD. Furthermore, we estimated the event-free survival probabilities for MACCE by using the Kaplan-Meier method. Cumulative incidence rates of MACCE in the long term significantly differed among the groups separated using the CKD-EPI equation (P ¼ 0.014) (Figure 3) . Similar findings were seen in our study using the MDRD Study equation. We observed similar clinical outcomes up to 3 years between the non-CKD and mild CKD groups when using the CKD-EPI equation, whereas a significant diversion in MACCE was observed afterward. Therefore, we think that the CKD-EPI creatinine equation could be useful along with the MDRD Study equation. However, we considered the fact that there is still little evidence using the CKD-EPI equation, and in fact, the Japanese coefficient-modified MDRD Study equation is recommended for use in clinical practice by Japanese guidelines. Therefore, we believe that further studies are necessary to evaluate the clinical significance of the Japanese coefficient-modified CKD-EPI equation.
One limitation of the present study was that our study subjects were not evaluated for the presence of structural kidney disease, such as abnormal ultrasound findings or proteinuria. Therefore, we might not have accurately defined and evaluated patients with mild CKD whose eGFR was >60 mL/min/1.73 m 2 . However, we consider that a simple separation determined by eGFR is both useful and reasonable in daily clinical practice, especially in secondary prevention of coronary artery disease.
In conclusion, mild CKD was associated with higher rate of MACCE in the long term in patients with ACS after PCI, but not in the short term. In addition, mild CKD as well as eGFR estimated by the new Japanese equation were found to be independent predictors of negative long-term outcomes in patients with ACS after adjusting for confounding variables. Careful intervention for mild CKD should be considered from the early stage in the secondary prevention of ACS.
